Caplight Directory>Companies>NeuroGenesis-preview>Neurogenesis


NeuroGenesis

NeuroGenesis

Private
Rochester, New YorkAI, Data & Cloud Infrastructurehttps://www.neurogenesis.com/

Last Round

Series A

Mar 11, 2022

Total Funding Raised

$10M

Company Overview

NeuroGenesis is a clinical-stage cellular therapy company that develops treatments for neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

Sector

AI, Data & Cloud Infrastructure

Verticals

Synthetic Data, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Usage-Based SaaS, Subscription SaaS, Freemium

AI Layer

Infrastructure

Keywords

synthetic EEG datasynthetic data generationsynthetic dataEEG datasynthetic data platformneurotechnologyneurotechgenerative AIgenerative adversarial networkGANAI training dataAI model trainingAI infrastructureelectroencephalography datamedical AIB2B SaaSmock datafake data

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuroGenesis Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NeuroGenesis Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMar 11, 2022
View all Funding Rounds

NeuroGenesis Investors

Notable investors and investment history

InvestorRounds
Excell PartnersSeries A
Morgan StanleySeries A
Rhodium VenturesSeries A
New York VenturesSeries A
View all Investors

NeuroGenesis Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeuroGenesis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeuroGenesis's valuation, stock price, and market status.

Firmographic Details

HeadquartersRochester, New York
Year Founded2018
Last FundingMar 11, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.